Chimeric Botulinum Neurotoxin Retention
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cosmetic treatments using clostridial toxin-based therapeutics, such as botulinum neurotoxin (BoNT), face challenges with toxin diffusion away from the administration site, leading to undesirable side effects and potential systemic neurological risks.
Innovation Solution
A modified BoNT/A is developed, comprising a BoNT/A light-chain and translocation domain, along with a BoNT/B receptor binding domain (HC domain), which enhances retention at the administration site and prolongs the duration of action to 6-9 months, while improving safety.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If unmodified BoNT/A is administered to treat facial lines, then the treatment provides muscle relaxation and wrinkle reduction, but the toxin diffuses away from the administration site causing side effects and safety concerns
Solution Approach 1:
The patent applies composite materials by creating a chimeric toxin that combines the light chain and translocation domain of BoNT/A with the heavy chain of BoNT/B. This composite structure integrates the muscle-paralyzing capability of BoNT/A with the reduced diffusion properties of BoNT/B, achieving both efficacy and safety improvements
Solution Approach 2:
The patent changes the molecular parameters of the toxin by modifying the amino acid sequence and structural composition. Specifically, it alters the receptor binding domain to match BoNT/B characteristics while retaining the catalytic domain of BoNT/A, thereby changing the diffusion parameter without sacrificing therapeutic effect
2Duration of action of moving object
If unmodified BoNT/A is administered at higher doses to extend treatment duration, then the duration of action increases, but toxin diffusion and systemic side effects increase
Solution Approach 1:
The patent changes the molecular parameters of the toxin by modifying the amino acid sequence and structural composition. Specifically, it alters the receptor binding domain to match BoNT/B characteristics while retaining the catalytic domain of BoNT/A, thereby changing the diffusion parameter without sacrificing therapeutic effect
Solution Approach 2:
The patent applies composite materials by creating a chimeric toxin that combines the light chain and translocation domain of BoNT/A with the heavy chain of BoNT/B. This composite structure integrates the muscle-paralyzing capability of BoNT/A with the reduced diffusion properties of BoNT/B, achieving both efficacy and safety improvements
3Duration of action of stationary object
If repeated administrations of BoNT/A are performed to maintain treatment effect, then the duration of cosmetic improvement is extended, but the frequency of injections increases and safety risks accumulate
Solution Approach 1:
The patent changes the molecular parameters of the toxin by modifying the amino acid sequence and structural composition. Specifically, it alters the receptor binding domain to match BoNT/B characteristics while retaining the catalytic domain of BoNT/A, thereby changing the diffusion parameter without sacrificing therapeutic effect
Solution Approach 2:
The patent applies partial or excessive action by administering a single dose of the modified toxin that provides prolonged effect (6-9 months) beyond what conventional doses achieve. The modified toxin's reduced diffusion allows higher effective concentration at the target site for extended periods, reducing the need for frequent re-administration
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The modified BoNT/A allows for higher doses to be administered safely, providing longer-lasting cosmetic treatments with reduced frequency of administration and improved safety profile compared to unmodified BoNT/A.
Implementation Method 1
BoNT/A selectively inhibits the release of acetylcholine from the presynaptic nerve terminals and thus blocks cholinergic transmission at the neuromuscular junction inducing a reduction in the muscle contraction and muscle tone
Implementation Method 2
The increased charge promotes electrostatic interactions between the polypeptide and anionic extracellular components, thereby promoting binding between the polypeptide and cell surface
Data Source
AI summary
The present invention provides a modified BoNT/A for use in treating facial lines, wherein the modified BoNT/A is administered by intramuscular injection at a plurality of sites of the face of the subject, wherein the modified BoNT/A is administered by way of a unit dose of greater than 1754 pg (e.g. greater than 1800 pg) of modified BoNT/A per site, wherein the plurality of sites are selected from: up to two sites of a corrugator muscle and one site of a procerus muscle for treating glabellar lines, up to five sites of a frontalis muscle for treating forehead lines, and up to three sites of an orbicularis oculi muscle for treating lateral canthal lines, wherein the total dose of modified BoNT/A administered during the treatment is up to 88,000 pg, and wherein the modified BoNT/A comprises a BoNT/A light-chain and translocation domain (HN domain), and a BoNT/B receptor binding domain (HC domain).